Regenxbio Inc (RGNX)

Name: Regenxbio Inc (RGNX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Regenxbio Inc (RGNX)

Stock Card

$9.32

$-0.18 (-1.89%)

As on 01-Sep-2026 16:28EDT

Market cap

$638 Mln

Revenue (TTM)

$174 Mln

P/E Ratio

P/B Ratio

8.6

Div. Yield

0 %

Regenxbio Inc (RGNX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 9.28 High: 9.62

52 Week Range

Low: 5.46 High: 16.19

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-3.4
Debt to Equity

0
Book Value

$--
EPS

$-3.8
Face value

--
Shares outstanding

66,013,192

10 Years Aggregate

CFO

$-395.60 Mln

EBITDA

$-754.26 Mln

Net Profit

$-684.97 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Regenxbio Inc (RGNX)	-35.3	-3.8	33.0	4.4	-19.2	-22.0	-2.3
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Regenxbio Inc (RGNX)	86.3	-56.6	-20.9	-30.6	-27.9	10.7	-2.3
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Regenxbio Inc (RGNX)	9.3	637.7	174.5	-196.4	-88.5	-225.1	--	8.6
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	260.3	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	71.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.9	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	363.8	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	538.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	583.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	353.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Regenxbio Inc (RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary... adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Read more

President, CEO & Director

Mr. Kenneth T. Mills
President, CEO & Director

Mr. Curran M. Simpson M.S.
Headquarters

Rockville, MD
Website

https://www.regenxbio.com

FAQs for Regenxbio Inc (RGNX)

What is the current share price of Regenxbio Inc (RGNX) Today?

The share price of Regenxbio Inc (RGNX) is $9.32 (NASDAQ) as of 01-Sep-2026 16:28 EDT. Regenxbio Inc (RGNX) has given a return of -19.25% in the last 3 years.

What is the current PB & PE ratio of Regenxbio Inc (RGNX)?

Since, TTM earnings of Regenxbio Inc (RGNX) is negative, P/E ratio is not available.
The P/B ratio of Regenxbio Inc (RGNX) is 8.62 times as on 28-Aug-2026, a 66 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-3.84	7.25
2024	-1.73	1.51
2023	-3.00	2.53
2022	-3.50	1.90
2021	11.28	1.89

What is the 52 Week High and Low of Regenxbio Inc (RGNX)?

The 52-week high and low of Regenxbio Inc (RGNX) are Rs 16.19 and Rs 5.46 as of 02-Sep-2026.

What is the market cap of Regenxbio Inc (RGNX)?

Regenxbio Inc (RGNX) has a market capitalisation of $ 638 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Regenxbio Inc (RGNX)?

Before investing in Regenxbio Inc (RGNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.